|
Sep 27
|
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
|
|
Sep 27
|
Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary di...
|
|
Sep 27
|
TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
|
|
Sep 26
|
Is Johnson & Johnson (JNJ) the Best Stock To Buy Right Now According To Billionaire Cliff Asness?
|
|
Sep 26
|
Johnson & Johnson (JNJ): Leveraging Innovation for Sustained Market Leadership
|
|
Sep 26
|
Johnson & Johnson (JNJ): A Good Undervalued Blue Chip Stock to Buy According to Analysts
|
|
Sep 26
|
Johnson & Johnson (JNJ): A Good Holding Company Stock to Buy Now
|
|
Sep 25
|
Johnson & Johnson (JNJ): Hedge Funds Are Bullish On This Trending AI Stock Right Now
|
|
Sep 25
|
37% Of This Johnson & Johnson Insider's Holdings Were Sold
|
|
Sep 25
|
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
|
|
Sep 24
|
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
|
|
Sep 9
|
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
|
|
Sep 9
|
J&J’s Rybrevant combo for NSCLC remains better than SOC after three years
|
|
Sep 9
|
Three Things To Know To Build A Dividend Portfolio For Passive Income
|
|
Sep 8
|
Johnson & Johnson (JNJ): A Magic Formula Stock You Should Pay Attention To
|
|
Sep 8
|
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
|
|
Sep 6
|
Judge orders J&J to pay Auris investors more than $1B for merger violations
|
|
Sep 5
|
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
|
|
Sep 5
|
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
|
|
Sep 5
|
Johnson & Johnson Gets Plaintiff Lawyer's Support on Upsized Talc Settlement Plan
|